Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Pens Drug Repositioning Pact with Abbott

NEW YORK (GenomeWeb News) - Gene Logic said today that it has signed a drug-repositioning agreement with Abbott that covers multiple clinical drug candidates that have passed Phase I human clinical trials.
Gene Logic said it stands to receive milestone payments for each new drug candidate that Abbott reenters into clinical development, as well as royalties for drug candidates that make it to market.
Gene Logic also will have the option to an exclusive license to any new drug candidate that Abbott chooses not to pursue. In such a case, Gene Logic would pay royalties to Abbott.
A Gene Logic spokeswoman said this open-ended agreement is the first such agreement it has entered with Abbott. Under its drug repositioning program, Gene Logic has partnerships with Pfizer, Roche, and other pharmaceutical companies.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.